Skip to main content
. 2022 Nov;33(11):2094–2107. doi: 10.1681/ASN.2022030306

Figure 3.

Figure 3.

eGFR by acute percentage decline categories for dapagliflozin and placebo. The annual eGFR decline from week 2 to the end of treatment for (A) the dapagliflozin group and (B) the placebo group. (C) The annual eGFR decline from week 2 to the end of treatment as a function of acute changes in eGFR in the placebo and dapagliflozin group.